臨床血液
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
臨床研究
中悪性度非ホジキンリンパ腫に対するWeekly CHOP療法
—7施設による共同研究—
小林 政英佐尾 浩水田 秀一神谷 修小原 寛治永田 紘一郎竹山 英夫渡辺 英二山田 博豊水野 晴光山雄 久美堀田 知光大西 一功川島 康平平林 憲之加藤 良一小栗 隆平林 紀男社本 幹博原 一夫
著者情報
ジャーナル 認証あり

1990 年 31 巻 10 号 p. 1656-1663

詳細
抄録

Between 1985 and 1988, 49 previously untreated patients with intermediate-grade non-Hodgkin's lymphoma (LSG classification large cell 35 including 11 large cell immunoblastic by Working Formulation, medium-sized cell 7, mixed 7) were treated with the Weekly CHOP regimen (three successive weekly administration of cyclophosphamide, doxorubicin, vincristine and prednisolone) as a cooperative group study by seven institutes (Nagoya Lymphoma Study Group).
Complete remission was achieved in 63.3% with Weekly CHOP alone and finally in 79.6% after the addition of radiotherapy and/or combination chemotherapies including etoposide, methotrexate, procarbazine, bleomycin. Patients with T cell phenotype, high grade PS and the presence of bulky mass had significantly lower rates of CR. After a median follow-up 36 months Kaplan-Meier estimates showed that overall survival was 60.4%, disease-free furvival 51.4% and relapse-free survival 64.6%.
The major toxicities were alopecia, leukopenia, infection, neuropathy and gastrointestinal symptoms. No treatment-related deaths were observed.
Survival was adversely affected by high LDH level, poor PS, T cell phenotype, the presence of B symptoms and the bulky mass. But these characteristics gave no significant effects on relapse rate and relapse-free survival. Thus, Weekly CHOP is an effective treatment for intermediate-grade NHL.

著者関連情報
© 1990 一般社団法人 日本血液学会
前の記事 次の記事
feedback
Top